MRI Scans at Triple the Speed, and Just as Sharp
By utilizing advances in parallel imaging, scientists cut the time needed for diagnostic MRI scans from 18 to 6.5 minutes, without a noticeable loss in quality.
NEWS
Beyond Antibodies: From CTAD, New Attempts at Outflanking Alzheimer’s
Data from early trials hint that new therapeutics could take down APP, express ApoE2, or fix inflammatory and metabolic dysfunction in AD.
Some Alzheimer’s Blood Tests Are Racing Toward IVD Certification
Vendors of plasma p-tau217-based tests are filing with U.S. and European regulators for approval of fully automated, in vitro diagnostics.
Biomarkers Suggest Black and Hispanic People Less Likely to Have Amyloid
To some, the findings suggest that non-AD pathologies, driven by other comorbidities, might contribute to cognitive decline in these populations.
AI to Spot ARIA? FDA Says Yes
The commercial software icobrain aria sharpened radiologists’ ability to accurately detect ARIA-E and ARIA-H. The FDA approved the technology for clinical use November 7.
Fully Loaded: Secondary Prevention Studies of Lecanemab, Donanemab
In Madrid, researchers touted the benefits of plasma prescreening and showed baseline data on these early AD populations. Meanwhile, remternetug has begun Phase 3.
Tau Modification Drugs Take a Hit with Negative Trial
Lilly’s Phase 2 trial of its O-GlcNAcase inhibitor ceperognastat failed to meet clinical endpoints. The drug’s adverse events suggest potential off-target effects.
Finally, Therapeutic Antibodies Start to Reduce Tangles
Bepranemab results bolster hopes for antibodies targeting tau’s middle section. Whether tangle clearance will improve clinical outcomes remains unclear.
SPOTLIGHT
From Madrid, News on Underrepresented Groups, Drug Trials, MRI and Blood Tests
This week, more news from CTAD. Alzheimerologists learned that, after years of trying to fold more underrepresented groups into trials, they were indeed reaching and screening more non-white people, but so many of them do not have brain amyloid that their enrollment percentage is still low. On the up side: tools keep improving. MRI is speeding up, AI can help spot ARIA, and p-tau blood tests are heading toward certification as in vitro diagnostics. And while two anti-amyloid antibodies are a nice start, researchers are trialing many more ways to fight AD.
Join The Conversation
Professional Resources
New in last 7 days
-
Grants
- New Items: 9
- Total Items: 284
-
Jobs
- New Items: 1
- Total Items: 32
-
Conference Calendar
- New Items: 1
- Total Items: 89
- Member Directory
Latest Comments